$IQV

STAUB W RICHARD sold $1.3M of IQV

STAUB W RICHARD (See Remarks) sold 5,500 shares of IQVIA HOLDINGS INC. (IQV) at $232.68 ($1.28M total) on 2026-08-03.

Original reporting
SEC EDGAR · STAUB W RICHARD
Published Aug 4, 2026, 9:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 4, 2026, 9:17 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$IQV
Neutral
medium confidence
Mentioned
$IQV
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IQVNeutralLow
01

Why it matters

The only new fact is the reported open-market sale size, price, and post-transaction holdings; it does not include any company-specific operational or financial update.

02

Market read

Traders may note the insider sale for sentiment, but there is no fundamental catalyst in the filing.

03

What to watch

Insider sales can be driven by diversification, taxes, or pre-existing personal liquidity needs, and the filing does not indicate any change in IQVIA’s outlook.

Relevance 6/10Novelty 3/10Timing: filed 2026-08-04 after-hours; sale executed 2026-08-03

Background

The article is an SEC Form 4 insider transaction disclosure for IQVIA Holdings Inc.

Company-level read

Ticker impact

$IQVNeutralMedium confidence
Context

IQVIA Form 4 shows officer Richard Staub sold 5,500 shares at $232.68 on 2026-08-03 for about $1.28M.

Expected impact

Likely minimal near-term impact; any effect would be sentiment-only and typically fades.

Evidence & confidence

The filing is a primary-source Form 4, but it provides no earnings, guidance, deal, or regulatory catalyst. Insider sales are common and often not predictive without additional context.

Market effects

No clear sector read-through from a single insider sale at IQVIA.

None indicated.

None indicated.

Counterpoint

The absence of a 10b5-1 plan could be interpreted by some traders as less routine, potentially adding short-term skepticism.

Key entities

  • IQVIA Holdings Inc.

    Subject of the Form 4 insider transaction disclosure.

  • STAUB W RICHARD

    Officer who sold 5,500 shares of IQVIA on 2026-08-03.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$IQVHighAI 9/10

Will IQVIA’s Upgraded 2026 Guidance and Bookings Strength Change IQVIA Holdings' (IQV) Narrative

IQVIA Holdings (IQV) reported Q2 earnings that beat expectations, with adjusted earnings up 12.1% and revenue up 8.7% year over year. The company raised its 2026 guidance for revenue, adjusted EBITDA, and earnings, citing strong bookings and acquisitions. Management attributes the upgrade to broad-based demand and operational efficiency, including AI-driven initiatives like IQVIA.ai. The stock is projected to reach $20.4 billion in revenue and $2.0 billion in earnings by 2029, representing a 5%

$IQVMed

How IQVIA’s Medera Cardiac Gene Therapy Alliance and Raised 2026 Outlook Will Impact IQV (IQV) Investors

IQVIA Inc. said it raised full-year 2026 revenue guidance to US$17.28–US$17.48 billion, with Q3 outlook of US$4.32–US$4.39 billion, alongside reporting Q2 results and buyback activity. IQVIA also announced a collaboration with Medera Inc. on cardiac gene therapies and human-based drug discovery, linking IQVIA trial and platform capabilities to Medera programs.

$IQVMed

5 Insightful Analyst Questions From IQVIA’s Q2 Earnings Call

IQVIA reported Q2 CY2026 results with revenue of $4.37B versus $4.30B estimates and adjusted EPS of $3.15 versus $3.03, with adjusted EBITDA of $994M. Management cited 6% organic growth and strong net new bookings. Full-year revenue guidance was lifted to $17.38B and adjusted EPS to $12.90. Analysts discussed bookings, outsourcing, AI, M&A, and margins.

Med

An IQVIA CEO Sold $26.1 Million as Bookings Hit a Record $3.15 Billion

IQVIA Holdings CEO sold about $26.1 million of stock appreciation rights with a Feb 2027 expiration, while retaining a large share position, according to the filing and article. The company reported Q2 revenue up 8.7% to $4.37B, adjusted EPS up 12.1% to $3.15, and record clinical bookings of $3.15B, raising full-year guidance to $17.475B.